TIROCAP CAPSULE

Country: Կանադա

language: անգլերեն

source: Health Canada

buyitnow

SPC SPC (SPC)
17-06-2021

active_ingredient:

LEVOTHYROXINE SODIUM

MAH:

IBSA INSTITUT BIOCHIMIQUE SA

ATC_code:

H03AA01

INN:

LEVOTHYROXINE SODIUM

dosage:

137MCG

pharmaceutical_form:

CAPSULE

composition:

LEVOTHYROXINE SODIUM 137MCG

administration_route:

ORAL

units_in_package:

100

prescription_type:

Prescription

therapeutic_area:

THYROID AGENTS

leaflet_short:

Active ingredient group (AIG) number: 0107794013; AHFS:

authorization_status:

APPROVED

authorization_date:

2021-06-21

SPC

                                _TIROCAP™ (levothyroxine sodium capsules) _
_Page 1 of 32_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TIROCAP™
Levothyroxine Sodium capsule
Capsules,13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125
mcg,
137 mcg, 150 mcg, 175 mcg and 200 mcg, oral
Thyroid Hormone
ATC Code: H03AA01
Institut Biochimique SA (IBSA)
Via del Piano 266
CH-6915 Pambio-Noranco,
Switzerland
Imported by:
Progress Therapeutics Inc.
14-320 Harry Walker Parkway North
Newmarket ON
Canada, L3Y 7B4
Date of Initial Authorization:
November 25, 2020
Date of Revision:
June 17, 2021
Submission Control No: 248553
_ _
_TIROCAP™ (levothyroxine sodium capsules) _
_Page 2 of 32_
TABLE OF CONTENTS
TABLE OF
CONTENTS.......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 4
1
INDICATIONS
...........................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics
..........................................................................................................
4
2
CONTRAINDICATIONS
...........................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................. 5
4
DOSAGE AND ADMINISTRATION
.........................................................................
5
4.1
Dosing
Considerations.....................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................. 6
4.3
Administration...................................................................................................
9
4.4
Missed
Dose.....................................................................................................
9
5
OVER
                                
                                read_full_document
                                
                            

documents_in_other_languages

SPC SPC ֆրանսերեն 17-06-2021